FY2025 Earnings Estimate for Merus Issued By Leerink Partnrs

Merus N.V. (NASDAQ:MRUS) – Investment analysts at Leerink Partnrs boosted their FY2025 earnings per share (EPS) estimates for shares of Merus in a research report issued on Sunday, November 2nd. Leerink Partnrs analyst A. Berens now anticipates that the biotechnology company will post earnings of ($6.13) per share for the year, up from their prior forecast of ($6.63). Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Merus’ current full-year earnings is ($3.85) per share. Leerink Partnrs also issued estimates for Merus’ Q4 2025 earnings at ($1.29) EPS, FY2026 earnings at ($5.28) EPS and FY2027 earnings at ($5.45) EPS.

MRUS has been the subject of several other research reports. Wells Fargo & Company reissued an “equal weight” rating and set a $97.00 price target (up previously from $95.00) on shares of Merus in a research report on Monday, September 29th. UBS Group lowered shares of Merus from a “buy” rating to a “neutral” rating and increased their target price for the stock from $72.00 to $97.00 in a report on Tuesday, September 30th. Guggenheim reaffirmed a “neutral” rating and set a $97.00 price target (down previously from $109.00) on shares of Merus in a research report on Tuesday, September 30th. Barclays reaffirmed an “equal weight” rating and issued a $97.00 price target (down previously from $112.00) on shares of Merus in a research note on Tuesday, September 30th. Finally, Leerink Partners reiterated a “market perform” rating and set a $97.00 target price (up previously from $95.00) on shares of Merus in a report on Monday, October 6th. Four analysts have rated the stock with a Buy rating, fourteen have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Merus presently has an average rating of “Hold” and a consensus price target of $92.35.

Merus Stock Performance

Shares of Merus stock opened at $95.04 on Wednesday. Merus has a 52-week low of $33.19 and a 52-week high of $95.30. The company’s 50 day moving average price is $82.21 and its 200-day moving average price is $64.45. The stock has a market capitalization of $7.21 billion, a price-to-earnings ratio of -17.93 and a beta of 1.26.

Merus (NASDAQ:MRUS) last announced its quarterly earnings data on Tuesday, August 5th. The biotechnology company reported ($2.23) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($1.06). Merus had a negative net margin of 673.31% and a negative return on equity of 52.99%. The company had revenue of $8.83 million during the quarter, compared to the consensus estimate of $9.77 million.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the stock. CWM LLC grew its stake in shares of Merus by 299.0% in the second quarter. CWM LLC now owns 802 shares of the biotechnology company’s stock worth $42,000 after acquiring an additional 601 shares during the last quarter. Farther Finance Advisors LLC grew its position in Merus by 10,400.0% during the 3rd quarter. Farther Finance Advisors LLC now owns 525 shares of the biotechnology company’s stock valued at $49,000 after purchasing an additional 520 shares during the last quarter. Caitong International Asset Management Co. Ltd increased its stake in Merus by 955.3% during the 1st quarter. Caitong International Asset Management Co. Ltd now owns 1,794 shares of the biotechnology company’s stock valued at $76,000 after purchasing an additional 1,624 shares in the last quarter. US Bancorp DE lifted its stake in shares of Merus by 324.1% in the first quarter. US Bancorp DE now owns 2,935 shares of the biotechnology company’s stock worth $124,000 after buying an additional 2,243 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Merus by 15.7% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,674 shares of the biotechnology company’s stock valued at $141,000 after buying an additional 362 shares during the last quarter. Hedge funds and other institutional investors own 96.14% of the company’s stock.

Merus Company Profile

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.